Search

Your search keyword '"Josephs, Debra"' showing total 364 results

Search Constraints

Start Over You searched for: Author "Josephs, Debra" Remove constraint Author: "Josephs, Debra"
364 results on '"Josephs, Debra"'

Search Results

1. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

2. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4

3. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes

4. Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first wave

5. Update on the prognostic value of a novel immune-related toxicity grading system (OST score) in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICI).

6. Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.

9. A cohort profile of the Graham Roberts study cohort

14. Cohort profile: King’s Health Partners bladder cancer biobank

15. Supplementary figures from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer

16. Supplementary Table S1 from Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling

17. Data from Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling

18. Supplementary Materials and Methods from Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling

19. Supplementary Figure Legends from Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling

20. Supplementary Figure S1 from Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling

25. Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study

26. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes

29. [99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression.

30. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

31. Additional file 1 of Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19

32. AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper

33. Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data

35. Safe Provision of Systemic Anti-Cancer Treatment for Urological Cancer Patients During COVID-19: A Tertiary Centre Experience in the First Wave of COVID-19

36. The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre

38. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

41. Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments

42. Abstract LB004: Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial

44. IgG4 subclass antibodies impair antitumor immunity in melanoma

45. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2

46. The impact of COVID-19 on delivery of systemic anti-cancer treatment in urological cancer patients: A comparison with 2019 data from Guy’s Cancer Center.

47. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients

Catalog

Books, media, physical & digital resources